Luo P - Search Results

1

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors.

Wen Y, Lin A, Zhu W, Wei T, Luo P, Guo L, Zhang J. Wen Y, et al. Among authors: luo p. Front Pharmacol. 2021 Jun 7;12:645862. doi: 10.3389/fphar.2021.645862. eCollection 2021. Front Pharmacol. 2021. PMID: 34163353 Free PMC article.

2

Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis.

Yi L, Zhang H, Zou J, Luo P, Zhang J. Yi L, et al. Among authors: luo p. Gynecol Oncol. 2018 Jun;149(3):612-619. doi: 10.1016/j.ygyno.2018.03.004. Epub 2018 Mar 9. Gynecol Oncol. 2018. PMID: 29530332 Review.

3

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis.

Fan J, Xia Z, Zhang X, Chen Y, Qian R, Liu S, You D, Zhang J, Luo P. Fan J, et al. Among authors: luo p. Onco Targets Ther. 2018 Mar 1;11:1105-1115. doi: 10.2147/OTT.S156170. eCollection 2018. Onco Targets Ther. 2018. PMID: 29535535 Free PMC article.

4

Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer.

Yi L, Zhang W, Zhang H, Shen J, Zou J, Luo P, Zhang J. Yi L, et al. Among authors: luo p. Drug Des Devel Ther. 2018 Aug 7;12:2455-2466. doi: 10.2147/DDDT.S169627. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30122902 Free PMC article.

5

The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.

Fan J, Fong T, Xia Z, Zhang J, Luo P. Fan J, et al. Among authors: luo p. Cancer Med. 2018 Oct;7(10):4993-5005. doi: 10.1002/cam4.1768. Epub 2018 Sep 19. Cancer Med. 2018. PMID: 30230699 Free PMC article.

6

Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis.

Zhang H, Shen J, Yi L, Zhang W, Luo P, Zhang J. Zhang H, et al. Among authors: luo p. J Cancer. 2018 Nov 11;9(23):4556-4567. doi: 10.7150/jca.27368. eCollection 2018. J Cancer. 2018. PMID: 30519362 Free PMC article.

7

Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.

Yi L, Fan J, Qian R, Luo P, Zhang J. Yi L, et al. Among authors: luo p. Int J Cancer. 2019 Jul 1;145(1):284-294. doi: 10.1002/ijc.32097. Epub 2019 Jan 20. Int J Cancer. 2019. PMID: 30613959 Free PMC article.

8

The efficacy of the new medical internship management network system.

Xia O, Ye J, Lin A, Chen Y, Guo W, Fong T, Qian R, Luo P, Zeng Z. Xia O, et al. Among authors: luo p. Medicine (Baltimore). 2019 Feb;98(7):e14435. doi: 10.1097/MD.0000000000014435. Medicine (Baltimore). 2019. PMID: 30762751 Free PMC article.

9

Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis.

Zou J, Zhu W, Meng H, Luo P, Zhang J. Zou J, et al. Among authors: luo p. Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):271-279. doi: 10.1080/17474124.2019.1570135. Epub 2019 Jan 25. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791765

10

Author's Reply to: Osimertinib and jaw osteonecrosis? A case report.

Yi L, Luo P, Zhang J. Yi L, et al. Among authors: luo p. Int J Cancer. 2019 Oct 1;145(7):2006-2007. doi: 10.1002/ijc.32398. Epub 2019 May 10. Int J Cancer. 2019. PMID: 31074838 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,047 results

Search Page

Filters